10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-, monohydrochloride | 59884-26-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-, monohydrochloride
• 英文别名: 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine;hydrochloride
• CAS: 59884-26-3
• 化学式: C21H27ClN2OS2
• 分子量: 423.0
• InChiKey: IXTOSJVLICGBLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.32
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  68.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• COMBINATION THERAPY FOR BIPOLAR DISORDER
  申请人：Oronsky Bryan T.

  公开号：US20090311347A1

  公开（公告）日：2009-12-17

  Treatment regimens for mood disorders that include administration of buprenorphine, alone or in combination with additional pharmacological agents are described. Specifically, treatment regimens that alleviate racing thoughts associated with bipolar disorder, and pharmaceutical compositions and kits for use therein are described. Dosing regimens, compositions, and kits including buprenorphine for treating mania associated with opioid withdrawal are also described.
• Combination Therapy for Bipolar Disorder
  申请人：Oronsky Bryan T.

  公开号：US20120231092A1

  公开（公告）日：2012-09-13

  Treatment regimens for mood disorders that include administration of buprenorphine, alone or in combination with additional pharmacological agents are described. Specifically, treatment regimens that alleviate racing thoughts associated with bipolar disorder, and pharmaceutical compositions and kits for use therein are described. Dosing regimens, compositions, and kits including buprenorphine for treating mania associated with opioid withdrawal are also described.
• US8138169B2
  申请人：——

  公开号：US8138169B2

  公开（公告）日：2012-03-20
• [EN] COMBINATION THERAPY FOR BIPOLAR DISORDER<br/>[FR] THÉRAPIE COMBINATOIRE POUR TROUBLE BIPOLAIRE
  申请人：XVASIVE INC

  公开号：WO2009126931A2

  公开（公告）日：2009-10-15

  Treatment regimens for mood disorders that include administration of buprenorphine, alone or in combination with additional pharmacological agents are described. Specifically, treatment regimens that alleviate racing thoughts associated with bipolar disorder, and pharmaceutical compositions and kits for use therein are described. Dosing regimens, compositions, and kits including buprenorphine for treating mania associated with opioid withdrawal are also described.